Opt 6.025 Adverse drug reaction referral plan. Opt 6.03 Certificate to use diagnostic pharmaceutical agents. Opt 6.04 Certificate to use therapeutic pharmaceutical agents and remove foreign bodies from eyes. Opt 6.05 Prescribing therapeutic pharmaceutical agents. Opt 6.01 NoteNote: The rules in this chapter apply only to optometrists licensed by the State of Wisconsin in accordance with ch. Opt 3 or ch. Opt 4, as applicable. Opt 6.01 NoteNote: To determine which pharmaceutical agents may be used by licensed optometrists, refer to ch. SPS 10, relating to the use of pharmaceutical agents by licensed optometrists. Opt 6.02Opt 6.02 Definitions. In this chapter: Opt 6.02(1)(1) “Adverse drug reaction” means an adverse, physical or psychological reaction experienced by a person resulting from diagnostic or therapeutic pharmaceutical agents administered by an optometrist that occurs within 24 hours after the drug is administered. An “adverse drug reaction” may be indicated by symptoms that include any of the following: Opt 6.02(1)(d)(d) Pale or red swelling of the periocular or periorbital tissues. Opt 6.02(1e)(1e) “Approved institution” means an institution approved by the board and accredited by a regional or professional accrediting organization which is recognized by the Council for Higher Education Accreditation or its successor or the federal department of education, in accordance with ss. 449.17 (1m) (b) and 449.18 (2) (a) 2., Stats. Opt 6.02(1n)(1n) “Classroom hour” means a minimum of 50 minutes of lecture, group discussion, or laboratory. “Classroom hour” does not include time spent working in a clinic other than as part of a laboratory directly associated with a course in pharmacology. Opt 6.02(1s)(1s) “Course of study in pharmacology” means a course of study completed in an approved institution after 1973 in general and clinical pharmacology as it relates to optometry with the characteristics described in s. 449.17 (1m) (b), Stats. For a course, such as a continuing education course, that does not lead to a degree in optometry to qualify as part of a course of study in pharmacology, the course must include at least one examination on course content. Opt 6.02(3)(3) “DPA” or “diagnostic pharmaceutical agent” means an agent authorized under s. SPS 10.02. Opt 6.02(6)(6) “TPA” or “therapeutic pharmaceutical agent” means an agent authorized under s. SPS 10.03. Opt 6.02 HistoryHistory: Cr. Register, December, 1990, No. 420, eff. 1-1-91; r. (3), Register, September, 1997, No. 501, eff. 10-1-97: CR 05-036: cr. (intro.) and (3) Register January 2006 No. 601, eff. 2-1-06; CR 06-116: renum. (1) to be (1m), cr. (1), r. (2) and (5), r. and recr. (3) and am. (6), Register May 2007 No. 617, eff. 6-1-07; correction in (1), (1m), (3), (6) made under s. 13.92 (4) (b) 7., Stats., Register November 2011 No. 671; CR 19-027: renum. (1) to (1) (intro.) and am., cr. (1) (a) to (i), r. (1m), cr. (1e), (1n), (1s), am. (3), r. (4), am. (6) Register January 2020 No. 769, eff. 2-1-20; correction in (1) (intro.) made under s. 35.17, Stats., Register January 2020 No. 769. Opt 6.025Opt 6.025 Adverse drug reaction referral plan. Opt 6.025(1)(1) An optometrist who wants to use diagnostic pharmaceutical agents authorized under s. SPS 10.02 or therapeutic pharmaceutical agents authorized under s. SPS 10.03 shall submit an adverse drug reaction referral plan prior to providing pharmaceutical agents. The plan shall be submitted to the department on an approved form in which the optometrist agrees to do all of the following: